1.
Ben-David U, Siranosian B, Ha G, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560(7718):325-330. doi:10.1038/s41586-018-0409-3.
1.
Loh P-R, Genovese G, Handsaker RE, et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018;559(7714):350-355. doi:10.1038/s41586-018-0321-x.
1.
Satpathy AT, Saligrama N, Buenrostro JD, et al. Transcript-indexed ATAC-seq for precision immune profiling. Nat Med. 2018;24(5):580-590. doi:10.1038/s41591-018-0008-8.
1.
Ben-David U, Ha G, Tseng Y-Y, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49(11):1567-1575. doi:10.1038/ng.3967.
1.
Tothova Z, Krill-Burger JM, Popova KD, et al. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017;21(4):547-555.e8. doi:10.1016/j.stem.2017.07.015.
1.
McPherson AW, Roth A, Ha G, et al. ReMixT: clone-specific genomic structure estimation in cancer. Genome Biol. 2017;18(1):140. doi:10.1186/s13059-017-1267-2.
1.
Veres A, Gosis BS, Ding Q, et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell. 2014;15(1):27-30. doi:10.1016/j.stem.2014.04.020.
1.
Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014;514(7520):54-8. doi:10.1038/nature13556.
1.
Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87. doi:10.1056/NEJMoa1409405.
1.
Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98. doi:10.1056/NEJMoa1408617.